Navigation Links
Promise of a New Lupus Treatment Is a Groundbreaking Achievement
Date:11/2/2009

uences of the disease. The fruits of that labor are starting to emerge. However, now is not the time for complacency. We must band together for lupus and continue to capitalize on the decades of research made possible through the efforts of the many dedicated researchers, physicians, people with lupus, and advocates.

"This announcement by HGS and GSK and the Overcoming Barriers to Drug Development in Lupus report, commissioned by the Lupus Foundation of America to outline recommendations on ways to overcome the barriers to lupus research, combine to serve as a call to action for a national coordinated effort to accelerate the pace of discovery, to develop more tolerable and effective treatments, and to ultimately find a cure for this perilous disease.

"We congratulate HGS and GSK on reaching this important milestone in lupus research and in the development of new therapies for lupus. We also extend our appreciation to the researchers and study volunteers who made this achievement possible: the physicians who have passionately committed to researching this disease, and the companies that continue to invest in finding new and necessary treatments for this devastating disease."

The next step in the process is for HGS and GSK to submit marketing applications in the United States, Europe and other regions during the first half of 2010. The LFA will closely follow this process, and continue to keep its constituents apprised of developments.

About Lupus

Lupus is an acute and chronic autoimmune disease in which the immune system is unbalanced, causing inflammation and tissue damage to virtually any organ in the body. Its health effects include heart attacks, strokes, seizures, miscarriages, and organ failure. Ninety percent of the people with lupus are women, and it is two to three times more common among African Americans, Hispanics/Latinos, Native Americans, and Asians. Lupus is unpredictable and
'/>"/>

SOURCE Lupus Foundation of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
2. New nanostructured thin film shows promise for efficient solar energy conversion
3. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
4. New Robotic Imaging Technology Holds Promise of Improved Cancer Care
5. Nanoemulsion vaccines show increasing promise
6. NIST/NIH micromagnets show promise as colorful smart tags for magnetic resonance imaging
7. Nano-sized electronic circuit promises bright view of early universe
8. Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired
9. New carbon material shows promise of storing large quantities of renewable electrical energy
10. New research field promises radical advances in optical technologies
11. Cord Blood America Salutes President-Elect Obamas Promise to Lift Restrictions on Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3
Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Old hay and Alpine ibex horns reveal how grasslands respond to climate change 2Old hay and Alpine ibex horns reveal how grasslands respond to climate change 3While Some New Agents Will Achieve Strong Sales the Migraine Drug Market Will Decline 241 3 Billion by 2018 as Generic Erosion Takes Toll on Top Sel 53712 1While Some New Agents Will Achieve Strong Sales the Migraine Drug Market Will Decline 241 3 Billion by 2018 as Generic Erosion Takes Toll on Top Sel 53712 2While Some New Agents Will Achieve Strong Sales the Migraine Drug Market Will Decline 241 3 Billion by 2018 as Generic Erosion Takes Toll on Top Sel 53712 3Emdeon Closes The Sentinel Group Acquisition Implements First Customer in Less than 30 Days 53708 1Emdeon Closes The Sentinel Group Acquisition Implements First Customer in Less than 30 Days 53708 2Emdeon Closes The Sentinel Group Acquisition Implements First Customer in Less than 30 Days 53708 3Emdeon Closes The Sentinel Group Acquisition Implements First Customer in Less than 30 Days 53708 4Scary ancient spiders revealed in 3 D models thanks to new imaging technique 9479 1Scary ancient spiders revealed in 3 D models thanks to new imaging technique 9479 2Scary ancient spiders revealed in 3 D models thanks to new imaging technique 9479 3